

**Supplementary Table S2.** Baseline Characteristics of the FAP $\alpha$  Study Population

| FAP $\alpha$ Score    | <80                 | $\geq$ 80            | Total               | p value             |
|-----------------------|---------------------|----------------------|---------------------|---------------------|
| Number (n=143)        | 90 (62.9%)          | 53 (37.1%)           | 143 (100%)          |                     |
| FAP $\alpha$ (median) | 20 (0-75)           | 100 (80-230)         | 50 (0-230)          | <0.001 <sup>a</sup> |
| Mean ( $\pm$ SD)      | 25.44 $\pm$ 23.57   | 111.32 $\pm$ 34.08   | 57.27 $\pm$ 50.06   |                     |
| Age (years) Median    | 47.96 (21.48-73.84) | 50.37 (26.65-81.35)  | 48.96 (21.48-81.35) | 0.213 <sup>a</sup>  |
| Mean ( $\pm$ SD)      | 48.44 $\pm$ 10.11   | 50.87 $\pm$ 11.71    | 49.34 $\pm$ 10.75   |                     |
| Total Treatment days  | 54.0 (44-69)        | 55.0 (45-70)         | 54.0 (44-70)        | 0.096 <sup>a</sup>  |
| Mean ( $\pm$ SD)      | 54.06 $\pm$ 4.90    | 55.49 $\pm$ 4.96     | 54.59 $\pm$ 4.96    |                     |
| BED (median)          | 86.4 (79.2-107.36)  | 87.12 (74.34-105.46) | 86.4 (74.34-107.36) | 0.013 <sup>a</sup>  |
| Mean ( $\pm$ SD)      | 85.13 $\pm$ 4.11    | 87.12 $\pm$ 4.80     | 85.87 $\pm$ 4.47    |                     |
| Gender                |                     |                      |                     | 0.443 <sup>b</sup>  |
| Female                | 23 (25.6%)          | 17 (32.1%)           | 40 (28.0%)          |                     |
| Male                  | 67 (74.4%)          | 36 (67.9%)           | 103 (72.0%)         |                     |
| Age                   |                     |                      |                     |                     |
| <48                   | 45 (50.0%)          | 23 (43.4%)           | 68 (47.6%)          | 0.491 <sup>b</sup>  |
| $\geq$ 48             | 45 (50.0%)          | 30 (56.6%)           | 75 (52.4%)          |                     |
| AJCC 2010 T-Stage     |                     |                      |                     | 0.002 <sup>b</sup>  |
| T <sub>1/2</sub>      | 52 (57.8%)          | 16 (30.2%)           | 68 (47.6%)          |                     |
| T <sub>3/4</sub>      | 38 (42.2%)          | 37 (69.8%)           | 75 (52.4%)          |                     |
| AJCC 2010 N-Stage     |                     |                      |                     | 0.604 <sup>b</sup>  |
| N <sub>0/1</sub>      | 44 (48.9%)          | 29 (54.7%)           | 73 (51.0%)          |                     |
| N <sub>2/3</sub>      | 46 (51.1%)          | 24 (45.3%)           | 70 (49.0%)          |                     |
| Chemotherapy          |                     |                      |                     | 0.208 <sup>b</sup>  |
| Yes                   | 68 (75.6%)          | 45 (84.9%)           | 113 (79.0%)         |                     |
| No                    | 22 (24.4%)          | 8 (15.1%)            | 30 (21.0%)          |                     |
| Comorbidity           |                     |                      |                     | 0.591 <sup>b</sup>  |
| No                    | 59 (65.6%)          | 32 (60.4%)           | 91 (63.6%)          |                     |
| Yes                   | 31 (34.4%)          | 21 (39.6%)           | 52 (36.4%)          |                     |
| Smoking               |                     |                      |                     | 0.728 <sup>b</sup>  |
| No                    | 41 (45.6%)          | 22 (41.5%)           | 63 (44.1%)          |                     |
| Yes                   | 49 (54.4%)          | 31 (58.5%)           | 80 (55.9%)          |                     |
| Betel Quid            |                     |                      |                     | 0.535 <sup>b</sup>  |
| No                    | 68 (75.6%)          | 43 (81.1%)           | 111 (77.6%)         |                     |
| Yes                   | 22 (24.4%)          | 10 (18.9%)           | 32 (22.4%)          |                     |
| Alcohol               |                     |                      |                     | 0.091 <sup>b</sup>  |
| No                    | 59 (65.6%)          | 42 (79.2%)           | 101 (70.6%)         |                     |
| Yes                   | 31 (34.4%)          | 11 (20.8%)           | 42 (29.4%)          |                     |
| OS (years) Median     | 9.64 (0.16-18.93)   | 8.03 (0.42-18.06)    | 8.53 (0.16-18.93)   | 0.032 <sup>a</sup>  |
| Mean ( $\pm$ SD)      | 9.77 $\pm$ 5.05     | 8.04 $\pm$ 4.34      | 9.13 $\pm$ 4.85     |                     |

<sup>a</sup>p-value was calculated using ANOVA test, 2-tailed. <sup>b</sup>Obtained using chi-square test, 2-tailed.  
 BED: biologically effective dose; OS: overall survival.